QIANG TONG to Neuroblastoma
This is a "connection" page, showing publications QIANG TONG has written about Neuroblastoma.
Connection Strength
3.395
-
YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression. J Transl Med. 2024 Dec 27; 22(1):1153.
Score: 0.625
-
Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity. Oncogene. 2023 09; 42(36):2673-2687.
Score: 0.567
-
Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity. Clin Transl Med. 2023 04; 13(4):e1235.
Score: 0.554
-
HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression. J Hematol Oncol. 2020 03 26; 13(1):24.
Score: 0.450
-
Long Noncoding RNA NHEG1 Drives ?-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5. Mol Ther. 2020 03 04; 28(3):946-962.
Score: 0.443
-
Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression. Theranostics. 2020; 10(4):1555-1571.
Score: 0.442
-
Targeting RBM10-Repressed RORB Activity in Liquid Condensates Inhibits Lysosomal Biogenesis and Neuroblastoma Progression via Affecting NF-?B Signaling. Adv Sci (Weinh). 2025 Nov; 12(44):e06131.
Score: 0.164
-
Targeting c-Myc transactivation by LMNA inhibits tRNA processing essential for malate-aspartate shuttle and tumour progression. Clin Transl Med. 2024 05; 14(5):e1680.
Score: 0.149